Enzalutamide (brand-name Xtandi) is a prostate cancer drug, originally developed by researchers at the University of California, Los Angeles (UCLA). UCLA has licensed the drug to Medivation Inc. through technology transfer. The life-saving prescription drug has demonstrated its utility in fighting prostate cancer, but controversy surrounds the manufacturing and distribution of the product. Xtandi, like many prescription drugs was developed by researchers at a university and heavily funded with public money. Ownership of the patent on Xtandi has allowed Medivation to inhibit production of generic versions of the drug, further creating barriers for equitable access and affordable pricing. As a generic version of Xtandi cannot be made or distributed, populations who could benefit from the drug remain unable to afford the medication and lack access to treatment. This discussion will discuss the role of the student-led organization, the Universities Allied for Essential Medicines (UAEM), in advocacy efforts to compel research universities to adopt policies that will ensure equitable and affordable access to drugs like Xtandi. This will include specific discussion of how UAEM is running a grass-roots advocacy campaign to better ensure access to Xtandi for needing populations, and how it mobilizes a diverse set of stakeholders champion health equity and access to medicines.